Alexion Announces the Appointment of John T. Mollen to Its Board of Directors

  Alexion Announces the Appointment of John T. Mollen to Its Board of
  Directors

   - Directors Joseph A. Madri and Larry L. Mathis to Retire in May 2014 -

Business Wire

CHESHIRE, Conn. -- April 17, 2014

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of
John “Jack” T. Mollen to the Company’s Board of Directors, effective
immediately. The Company also announced that Joseph A. Madri, Ph.D., M.D. and
Larry L. Mathis, will retire at the conclusion of the current term on May 5,
2014, after 22 years and 10 years of service to the Company, respectively.

“Jack has a remarkable track record as a leader and executive and brings
substantial operational experience in human resources and organizational
development to the Alexion Board. His expertise will be valuable to our
growing global organization and we are pleased to welcome him to the Alexion
Board of Directors,” said Max Link, Ph.D. Chairman of Alexion’s Board of
Directors.

Jack Mollen was most recently special advisor to the Chairman of EMC
Corporation and previously served as EMC's Executive Vice President, Human
Resources (HR) for 14 years. While at EMC, Mr. Mollen led the global human
resources function to ensure the availability of world-class talent to drive
business success and his responsibilities included executive, leadership, and
employee development; compensation and benefits; staffing; and all of the
people-related aspects of acquisition integration. Prior to joining EMC, Mr.
Mollen was Vice President of Human Resources at Citigroup Inc. Mr. Mollen
serves as a director for a number of not-for-profit and professional boards,
including the New England Healthcare Institute, the HR Policy Association,
Center on Executive Compensation, Worcester Polytechnic Institute Board of
Trustees and Chairman of its Compensation Committee, and as an advisory board
member for Working Mother magazine. Mr. Mollen received a bachelor’s degree in
economics from St. John Fisher College in Rochester, N.Y., and a master's
degree in labor relations from St. Francis University in Loretto, Pa.

“I am honored to join Alexion's Board of Directors at this exciting time in
the Company’s continuing global expansion. I look forward to playing an
integral role that will contribute to the fulfillment of Alexion’s unique
mission to develop and deliver innovative therapies for patients with severe
and life-threatening rare diseases,” said Mr. Mollen.

Alexion also announced the retirement of two long-standing directors who have
each made invaluable contributions to the Company’s growth and global
expansion during a combined 32 years of service.

Joseph A. Madri, M.D., Ph.D., who has been a director since the Company's
founding in 1992, is retiring from the Board after 22 years of outstanding
service to Alexion. Dr. Madri has been on the faculty of the Yale University
School of Medicine since 1980, and is currently a professor of pathology and
molecular, cellular and developmental biology. Dr. Madri also serves on the
editorial boards of numerous scientific journals and is the author of over 243
scientific publications. “Joe has served on Alexion’s Board with distinction
and we are grateful for his significant contributions to research and
scientific dialog and his dedicated tenure with Alexion,” said Leonard Bell,
M.D., Chief Executive Officer of Alexion Pharmaceuticals.

In addition, Larry L. Mathis is also retiring from the Board after a decade of
outstanding service to the Company. Since 1998 he has served as an executive
consultant with D. Peterson & Associates in Houston, providing counsel on
leadership, management, governance and strategy. Mr. Mathis was the founding
president and chief executive officer of The Methodist Hospital System in
Houston, having served that institution in various executive positions for 27
years, including 14 years as Chief Executive Officer before his retirement in
1997. “Larry has been an excellent Board member and we are thankful for his
commitment to the highest standards of corporate governance on Alexion’s Board
as well as his business insights in the healthcare industry,” said Dr. Bell.

About Alexion

Alexion is a biopharmaceutical company focused on serving patients with severe
and rare disorders through the innovation, development and commercialization
of life-transforming therapeutic products. Alexion is the global leader in
complement inhibition and has developed and markets Soliris^® (eculizumab) as
a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and
life-threatening disorders caused by chronic uncontrolled complement
activation. Soliris is currently approved in nearly 50 countries for the
treatment of PNH, and in the United States, European Union, Japan and other
countries for the treatment of aHUS. Alexion is evaluating other potential
indications for Soliris in additional severe and ultra-rare disorders beyond
PNH and aHUS, and is developing other highly innovative biotechnology product
candidates across multiple therapeutic areas. This press release and further
information about Alexion Pharmaceuticals can be found at:
www.alexionpharma.com.

[ALXN-G]

Contact:

Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Executive Director, Corporate Communications
or
(Media)
Kim Diamond, 203-439-9600
Senior Director, Corporate Communications
or
(Investors)
Rx Communications
Rhonda Chiger, 917-322-2569
 
Press spacebar to pause and continue. Press esc to stop.